Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 972

1.

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.

Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT.

Respir Res. 2020 Feb 10;21(1):47. doi: 10.1186/s12931-020-1307-4.

2.

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC.

Marwitz S, Turkowski K, Nitschkowski D, Weigert A, Brandenburg J, Reiling N, Thomas M, Reck M, Drömann D, Seeger W, Rabe KF, Savai R, Goldmann T.

Front Oncol. 2020 Jan 21;9:1550. doi: 10.3389/fonc.2019.01550. eCollection 2019.

3.

Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.

Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.

Int J Chron Obstruct Pulmon Dis. 2020 Jan 9;15:99-106. doi: 10.2147/COPD.S229794. eCollection 2020.

4.

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.

Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, Zhang B, Rice MS, Maroni J, Rowe P, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, Teper A.

ERJ Open Res. 2020 Jan 27;6(1). pii: 00204-2019. doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

5.

The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET.

Kahnert K, Föhrenbach M, Lucke T, Alter P, Trudzinski FT, Bals R, Lutter JI, Timmermann H, Söhler S, Förderreuther S, Nowak D, Watz H, Waschki B, Behr J, Welte T, Vogelmeier CF, Jörres RA.

Respir Res. 2020 Jan 20;21(1):28. doi: 10.1186/s12931-020-1293-6.

6.

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.

Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2993-3002. doi: 10.2147/COPD.S220861. eCollection 2019.

7.

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.

Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2979-2991. doi: 10.2147/COPD.S220850. eCollection 2019.

8.

High-sensitivity troponin I and all-cause mortality in patients with stable COPD: An analysis of the COSYCONET study.

Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fähndrich S, Blankenberg S, Rabe KF, Welte T, Jörres RA, Vogelmeier CF, Bals R, Watz H; German COSYCONET Cohort.

Eur Respir J. 2019 Dec 12. pii: 1901314. doi: 10.1183/13993003.01314-2019. [Epub ahead of print]

PMID:
31831579
9.

Electroencephalogram Source Connectivity in the Prediction of Electroconvulsive Therapy Outcome in Major Depressive Disorder.

Kirsten A, Seifritz E, Olbrich S.

Clin EEG Neurosci. 2020 Jan;51(1):10-18. doi: 10.1177/1550059419888338. Epub 2019 Nov 22.

PMID:
31752533
10.

CAT score single item analysis in patients with COPD: Results from COSYCONET.

Marietta von Siemens S, Alter P, Lutter JI, Kauczor HU, Jobst B, Bals R, Trudzinski FC, Söhler S, Behr J, Watz H, Waschki B, Bewig B, Jones PW, Welte T, Vogelmeier CF, Jörres RA, Kahnert K; COSYCONET study group; Names of participating study nurses.

Respir Med. 2019 Nov;159:105810. doi: 10.1016/j.rmed.2019.105810. Epub 2019 Nov 7.

PMID:
31739262
11.

Time-updated resting heart rate predicts mortality in patients with COPD.

Omlor AJ, Trudzinski FC, Alqudrah M, Seiler F, Biertz F, Vogelmeier CF, Welte T, Watz H, Waschki B, Brinker TJ, Andreas S, Fähndrich S, Alter P, Jörres RA, Böhm M, Bals R; German COSYCONET Cohort.

Clin Res Cardiol. 2019 Nov 16. doi: 10.1007/s00392-019-01572-1. [Epub ahead of print]

PMID:
31734762
12.

Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.

Nitschkowski D, Marwitz S, Kotanidou SA, Reck M, Kugler C, Rabe KF, Ammerpohl O, Goldmann T.

Clin Epigenetics. 2019 Nov 12;11(1):157. doi: 10.1186/s13148-019-0770-6.

13.

Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort.

Königsdorfer N, Jörres RA, Söhler S, Welte T, Behr J, Ficker JH, Bals R, Watz H, Lutter JI, Lucke T, Biertz F, Alter P, Vogelmeier CF, Kahnert K.

Patient Prefer Adherence. 2019 Oct 10;13:1711-1721. doi: 10.2147/PPA.S223438. eCollection 2019.

14.

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.

Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P.

Respir Med. 2019 Oct - Nov;158:59-66. doi: 10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22.

PMID:
31605923
15.

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort.

Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.

16.

Point-of-care biomarkers in asthma management: Time to move forward.

Alving K, Diamant Z, Lucas S, Magnussen H, Pavord ID, Piacentini G, Price D, Roche N, Sastre J, Thomas M, Usmani O, Bjermer L; Respiratory Effectiveness Group:; Biomarkers Working Group.

Allergy. 2019 Sep 10. doi: 10.1111/all.14045. [Epub ahead of print] No abstract available.

PMID:
31505025
17.

[Expert Workshop COPD: Lungs and Heart - Quite Often Ill Together].

Jany B, Bals R, Dreher M, Held M, Jany L, Rembert Koczulla A, Pfeifer M, Randerath W, Watz H, Wilkens H, Steinkamp G.

Pneumologie. 2019 Nov;73(11):651-669. doi: 10.1055/a-0914-9566. Epub 2019 Sep 9. German.

PMID:
31499562
18.

Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression.

Andreas S, Röver C, Heinz J, Straube S, Watz H, Friede T.

Respir Res. 2019 Aug 16;20(1):186. doi: 10.1186/s12931-019-1163-2.

19.

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.

Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M, Nandeuil MA.

Respir Res. 2019 Aug 9;20(1):180. doi: 10.1186/s12931-019-1142-7.

20.

Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.

Kuempers C, van der Linde LIS, Reischl M, Vogel W, Stellmacher F, Reck M, Heigener D, Rabe KF, Kirfel J, Perner S, Welker L.

Virchows Arch. 2020 Feb;476(2):261-271. doi: 10.1007/s00428-019-02632-7. Epub 2019 Aug 7.

PMID:
31392467

Supplemental Content

Loading ...
Support Center